Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2010 (2010), Article ID 876049, 12 pages
http://dx.doi.org/10.1155/2010/876049
Review Article

Therapeutic Implications of PPAR in Cardiovascular Diseases

1Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan
2Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan

Received 27 April 2010; Accepted 13 July 2010

Academic Editor: Antonio Brunetti

Copyright © 2010 Hiroshi Hasegawa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. B. Kannel, “Hazards, risks, and threats of heart disease from the early stages to symptomatic coronary heart disease and cardiac failure,” Cardiovascular Drugs and Therapy, vol. 11, 1, pp. 199–212, 1997. View at Publisher · View at Google Scholar · View at Scopus
  2. C. M. Lawes, S. V. Hoorn, and A. Rodgers, “Global burden of blood-pressure-related disease, 2001,” The Lancet, vol. 371, no. 9623, pp. 1513–1518, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. R. H. Knopp, “Drug treatment of lipid disorders,” New England Journal of Medicine, vol. 341, no. 7, pp. 498–511, 1999. View at Publisher · View at Google Scholar · View at Scopus
  4. H. E. Lebovitz, “Type 2 diabetes: an overview,” Clinical Chemistry, vol. 45, no. 8, pp. 1339–1345, 1999. View at Google Scholar · View at Scopus
  5. M. N. Ghazzi, J. E. Perez, T. K. Antonucci et al., “Cardiac and glycemic benefits of troglitazone treatment in NIDDM,” Diabetes, vol. 46, no. 3, pp. 433–439, 1997. View at Google Scholar · View at Scopus
  6. C. Jiang, A. T. Ting, and B. Seed, “PPAR-γ agonists inhibit production of monocyte inflammatory cytokines,” Nature, vol. 391, no. 6662, pp. 82–86, 1998. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass, “The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation,” Nature, vol. 391, no. 6662, pp. 79–82, 1998. View at Publisher · View at Google Scholar · View at Scopus
  8. N. Marx, U. Schönbeck, M. A. Lazar, P. Libby, and J. Plutzky, “Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells,” Circulation Research, vol. 83, no. 11, pp. 1097–1103, 1998. View at Google Scholar · View at Scopus
  9. K. Iijima, M. Yoshizumi, J. Ako et al., “Expression of peroxisome proliferator-activated receptor γ (PPARγ) in rat aortic smooth muscle cells,” Biochemical and Biophysical Research Communications, vol. 247, no. 2, pp. 353–356, 1998. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Benson, J. Wu, S. Padmanabhan, T. W. Kurtz, and H. A. Pershadsingh, “Peroxisome proliferator-activated receptor (PPAR)-γ expression in human vascular smooth muscle cells: inhibition of growth, migration, and c-fos expression by the peroxisome proliferator-activated receptor (PPAR)-γ activator troglitazone,” American Journal of Hypertension, vol. 13, no. 1, pp. 74–82, 2000. View at Google Scholar · View at Scopus
  11. H. Takano, T. Nagai, M. Asakawa et al., “Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-α expression in neonatal rat cardiac myocytes,” Circulation Research, vol. 87, no. 7, pp. 596–602, 2000. View at Google Scholar · View at Scopus
  12. V. Perissi, A. Aggarwal, C. K. Glass, D. W. Rose, and M. G. Rosenfeld, “A corepressor/coactivator exchange complex required for transcriptional activation by nuclear receptors and other regulated transcription factors,” Cell, vol. 116, no. 4, pp. 511–526, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Ogawa, J. Lozach, K. Jepsen et al., “A nuclear receptor corepressor transcriptional checkpoint controlling activator protein 1-dependent gene networks required for macrophage activation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 40, pp. 14461–14466, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. G. Pascual, A. L. Fong, S. Ogawa et al., “A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ,” Nature, vol. 437, no. 7059, pp. 759–763, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. J. R. Eun, H. K. Chang, Y. L. Won et al., “No association of Pro12Ala polymorphism of PPAR-γ gene with coronary artery disease in Korean subjects,” Circulation Journal, vol. 71, no. 3, pp. 338–342, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. L. Dongxia, H. Qi, L. Lisong, and G. Jincheng, “Association of peroxisome proliferator-activated receptorγ gene Pro12Ala and C161T polymorphisms with metabolic syndrome,” Circulation Journal, vol. 72, no. 4, pp. 551–557, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. E. Robinson and D. J. Grieve, “Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease,” Pharmacology and Therapeutics, vol. 122, no. 3, pp. 246–263, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. L. Nagy, P. Tontonoz, J. G. A. Alvarez, H. Chen, and R. M. Evans, “Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ,” Cell, vol. 93, no. 2, pp. 229–240, 1998. View at Publisher · View at Google Scholar · View at Scopus
  19. P. Tontonoz, L. Nagy, J. G. A. Alvarez, V. A. Thomazy, and R. M. Evans, “PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL,” Cell, vol. 93, no. 2, pp. 241–252, 1998. View at Publisher · View at Google Scholar · View at Scopus
  20. J. T. Huang, J. S. Welch, M. Ricote et al., “Interleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase,” Nature, vol. 400, no. 6742, pp. 378–382, 1999. View at Publisher · View at Google Scholar · View at Scopus
  21. R. Chen, F. Liang, J. Moriya et al., “Peroxisome proliferator-activated receptors (PPARs) and their agonists for hypertension and heart failure: are the reagents beneficial or harmful?” International Journal of Cardiology, vol. 130, no. 2, pp. 131–139, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. R. Ross, “Atherosclerosis—an inflammatory disease,” New England Journal of Medicine, vol. 340, no. 2, pp. 115–126, 1999. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Faggiotto, R. Ross, and L. Harker, “Studies of hypercholesterolemia in the nonhuman primate. I. Changes that lead to fatty streak formation,” Arteriosclerosis, vol. 4, no. 4, pp. 323–340, 1984. View at Google Scholar · View at Scopus
  24. A. C. Van der Wal, P. K. Das, A. J. Tigges, and A. E. Becker, “Adhesion molecules on the endothelium and mononuclear cells in human atherosclerotic lesions,” American Journal of Pathology, vol. 141, no. 6, pp. 1427–1433, 1992. View at Google Scholar · View at Scopus
  25. N. Marx, G. Sukhova, C. Murphy, P. Libby, and J. Plutzky, “Macrophages in human atheroma contain PPARγ: differentiation-dependent peroxisomal proliferator-activated receptor γ (PPARγ) expression and reduction of MMP-9 activity through PPARγ activation in mononuclear phagocytes in vitro,” American Journal of Pathology, vol. 153, no. 1, pp. 17–23, 1998. View at Google Scholar · View at Scopus
  26. M. Ricote, J. Huang, L. Fajas et al., “Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 13, pp. 7614–7619, 1998. View at Google Scholar · View at Scopus
  27. N. Marx, B. Kehrle, K. Kohlhammer et al., “PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis,” Circulation Research, vol. 90, no. 6, pp. 703–710, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. N. Marx, H. Duez, J.-C. Fruchart, and B. Staels, “Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells,” Circulation Research, vol. 94, no. 9, pp. 1168–1178, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. M. A. Bouhlel, B. Derudas, E. Rigamonti et al., “PPARγ activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties,” Cell Metabolism, vol. 6, no. 2, pp. 137–143, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. J. I. Odegaard, R. R. Ricardo-Gonzalez, M. H. Goforth et al., “Macrophage-specific PPARγ controls alternative activation and improves insulin resistance,” Nature, vol. 447, no. 7148, pp. 1116–1120, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. R. E. Law, W. P. Meehan, X.-P. Xi et al., “Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia,” Journal of Clinical Investigation, vol. 98, no. 8, pp. 1897–1905, 1996. View at Google Scholar · View at Scopus
  32. S. Goetze, X.-P. Xi, H. Kawano et al., “PPARγ-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells,” Journal of Cardiovascular Pharmacology, vol. 33, no. 5, pp. 798–806, 1999. View at Publisher · View at Google Scholar · View at Scopus
  33. W. A. Hsueh, S. Jackson, and R. E. Law, “Control of vascular cell proliferation and migration by PPAR-γ: a new approach to the macrovascular complications of diabetes,” Diabetes Care, vol. 24, no. 2, pp. 392–397, 2001. View at Google Scholar · View at Scopus
  34. Y. Takata, Y. Kitami, T. Okura, and K. Hiwada, “Peroxisome proliferator-activated receptor-γ activation inhibits interleukin-1β-mediated platelet-derived growth factor-α receptor gene expression via CCAAT/enhancer-binding protein-δ in vascular smooth muscle cells,” Journal of Biological Chemistry, vol. 276, no. 16, pp. 12893–12897, 2001. View at Publisher · View at Google Scholar · View at Scopus
  35. T. Okura, M. Nakamura, Y. Takata, S. Watanabe, Y. Kitami, and K. Hiwada, “Troglitazone induces apoptosis via the p53 and Gadd45 pathway in vascular smooth muscle cells,” European Journal of Pharmacology, vol. 407, no. 3, pp. 227–235, 2000. View at Publisher · View at Google Scholar · View at Scopus
  36. Y. Aizawa, J.-I. Kawabe, N. Hasebe, N. Takehara, and K. Kikuchi, “Pioglitazone enhances cytokine-induced apoptosis in vascular smooth muscle cells and reduces intimal hyperplasia,” Circulation, vol. 104, no. 4, pp. 455–460, 2001. View at Google Scholar · View at Scopus
  37. A. Sugawara, K. Takeuchi, A. Uruno et al., “Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-γ in vascular smooth muscle cells,” Endocrinology, vol. 142, no. 7, pp. 3125–3134, 2001. View at Publisher · View at Google Scholar · View at Scopus
  38. K. Takeda, T. Ichiki, T. Tokunou et al., “Peroxisome proliferator-activated receptor γ activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells,” Circulation, vol. 102, no. 15, pp. 1834–1839, 2000. View at Google Scholar · View at Scopus
  39. D. M. Tham, B. Martin-McNulty, Y.-X. Wang et al., “Angiotensin II is associated with activation of NF-κB-mediated genes and downregulation of PPARs,” Physiological Genomics, vol. 11, pp. 21–30, 2003. View at Google Scholar · View at Scopus
  40. S. M. Jackson, F. Parhami, X.-P. Xi et al., “Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 9, pp. 2094–2104, 1999. View at Google Scholar · View at Scopus
  41. V. Pasceri, H. D. Wu, J. T. Willerson, and E. T. H. Yeh, “Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-γ activators,” Circulation, vol. 101, no. 3, pp. 235–238, 2000. View at Google Scholar · View at Scopus
  42. H. Lee, W. Shi, P. Tontonoz et al., “Role for peroxisome proliferator-activated receptor α in oxidized phospholipid-induced synthesis of monocyte chemotactic protein-1 interleukin-8 by endothelial cells,” Circulation Research, vol. 87, no. 6, pp. 516–521, 2000. View at Google Scholar · View at Scopus
  43. U. Kintscher, S. Goetze, S. Wakino et al., “Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes,” European Journal of Pharmacology, vol. 401, no. 3, pp. 259–270, 2000. View at Publisher · View at Google Scholar · View at Scopus
  44. P. Delerive, F. Martin-Nizard, G. Chinetti et al., “Peroxisome proliferator-activated receptor activators inhibit thrombin- induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway,” Circulation Research, vol. 85, no. 5, pp. 394–402, 1999. View at Google Scholar · View at Scopus
  45. J. Han, D. P. Hajjar, J. M. Tauras, J. Feng, A. M. Gotto Jr., and A. C. Nicholson, “Transforming growth factor-β1 (TGF-β1) and TGF-β2 decrease expression of CD36, the type B scavenger receptor, through mitogen-activated protein kinase phosphorylation of peroxisome proliferator-activated receptor-γ,” Journal of Biological Chemistry, vol. 275, no. 2, pp. 1241–1246, 2000. View at Publisher · View at Google Scholar · View at Scopus
  46. J. J. Repa, S. D. Turley, J.-M. A. Lobaccaro et al., “Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers,” Science, vol. 289, no. 5484, pp. 1524–1529, 2000. View at Publisher · View at Google Scholar · View at Scopus
  47. A. Venkateswaran, B. A. Laffitte, S. B. Joseph et al., “Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXRα,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 22, pp. 12097–12102, 2000. View at Publisher · View at Google Scholar · View at Scopus
  48. P. Costet, Y. Luo, N. Wang, and A. R. Tall, “Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor,” Journal of Biological Chemistry, vol. 275, no. 36, pp. 28240–28245, 2000. View at Publisher · View at Google Scholar · View at Scopus
  49. A. Chawla, W. A. Boisvert, C.-H. Lee et al., “A PPARγ-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis,” Molecular Cell, vol. 7, no. 1, pp. 161–171, 2001. View at Publisher · View at Google Scholar · View at Scopus
  50. G. Chinetti, S. Lestavel, V. Bocher et al., “PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway,” Nature Medicine, vol. 7, no. 1, pp. 53–58, 2001. View at Publisher · View at Google Scholar · View at Scopus
  51. Q. N. Diep, M. E. Mabrouk, J. S. Cohn et al., “Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-γ,” Circulation, vol. 105, no. 19, pp. 2296–2302, 2002. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Iglarz, R. M. Touyz, F. Amiri, M.-F. Lavoie, Q. N. Diep, and E. L. Schiffrin, “Effect of peroxisome proliferator-activated receptor-α and -γ activators on vascular remodeling in endothelin-dependent hypertension,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 1, pp. 45–51, 2003. View at Publisher · View at Google Scholar · View at Scopus
  53. N. Marx, A. Imhof, J. Froehlich et al., “Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease,” Circulation, vol. 107, no. 15, pp. 1954–1957, 2003. View at Publisher · View at Google Scholar · View at Scopus
  54. S. W. M. van den Borne, J. Diez, W. M. Blankesteijn, J. Verjans, L. Hofstra, and J. Narula, “Myocardial remodeling after infarction: the role of myofibroblasts,” Nature Reviews Cardiology, vol. 7, no. 1, pp. 30–37, 2009. View at Publisher · View at Google Scholar · View at Scopus
  55. H. M. Piper, K. Meuter, and C. Schäfer, “Cellular mechanisms of ischemia-reperfusion injury,” Annals of Thoracic Surgery, vol. 75, no. 2, pp. S644–S648, 2003. View at Publisher · View at Google Scholar · View at Scopus
  56. N. G. Frangogiannis, C. W. Smith, and M. L. Entman, “The inflammatory response in myocardial infarction,” Cardiovascular Research, vol. 53, no. 1, pp. 31–47, 2002. View at Publisher · View at Google Scholar · View at Scopus
  57. Y. Onai, J.-I. Suzuki, T. Kakuta et al., “Inhibition of IκB phosphorylation in cardiomyocytes attenuates myocardial ischemia/reperfusion injury,” Cardiovascular Research, vol. 63, no. 1, pp. 51–59, 2004. View at Publisher · View at Google Scholar · View at Scopus
  58. I.-K. S. Aggeli, C. Gaitanaki, and I. Beis, “Involvement of JNKs and p38-MAPK/MSK1 pathways in H2O2-induced upregulation of heme oxygenase-1 mRNA in H9c2 cells,” Cellular Signalling, vol. 18, no. 10, pp. 1801–1812, 2006. View at Publisher · View at Google Scholar · View at Scopus
  59. M. R. Mehrabi, T. Thalhammer, P. Haslmayer et al., “The peroxisome proliferator-activated receptor gamma (PPARγ) is highly expressed in human heart ventricles,” Biomedicine and Pharmacotherapy, vol. 56, no. 8, pp. 407–410, 2002. View at Publisher · View at Google Scholar · View at Scopus
  60. P. J. H. Smeets, A. Planavila, G. J. Van Der Vusse, and M. Van Bilsen, “Peroxisome proliferator-activated receptors and inflammation: take it to heart,” Acta Physiologica, vol. 191, no. 3, pp. 171–188, 2007. View at Publisher · View at Google Scholar · View at Scopus
  61. T.-L. Yue, J. Chen, W. Bao et al., “In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone,” Circulation, vol. 104, no. 21, pp. 2588–2594, 2001. View at Google Scholar · View at Scopus
  62. N. Khandoudi, P. Delerive, I. Berrebi-Bertrand, R. E. Buckingham, B. Staels, and A. Bril, “Rosiglitazone, a peroxisome proliferator-activated receptor-γ, inhibits the Jun NH2-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury,” Diabetes, vol. 51, no. 5, pp. 1507–1514, 2002. View at Google Scholar · View at Scopus
  63. N. S. Wayman, Y. Hattori, M. C. Mcdonald et al., “Ligands of the peroxisome proliferator-activated receptors (PPAR-γ and PPAR-α) reduce myocardial infarct size,” FASEB Journal, vol. 16, no. 9, pp. 1027–1040, 2002. View at Publisher · View at Google Scholar · View at Scopus
  64. P. Zhu, L. Lu, Y. Xu, and G. G. Schwartz, “Troglitazone improves recovery of left ventricular function after regional ischemia in pigs,” Circulation, vol. 101, no. 10, pp. 1165–1171, 2000. View at Google Scholar · View at Scopus
  65. T. Shiomi, H. Tsutsui, S. Hayashidani et al., “Pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction,” Circulation, vol. 106, no. 24, pp. 3126–3132, 2002. View at Publisher · View at Google Scholar · View at Scopus
  66. H. Ikejima, T. Imanishi, H. Tsujioka et al., “Effect of pioglitazone on nitroglycerin-induced impairment of nitric oxide bioavailability by a catheter-type nitric oxide sensor,” Circulation Journal, vol. 72, no. 6, pp. 998–1002, 2008. View at Publisher · View at Google Scholar · View at Scopus
  67. J. S. Healey and S. J. Connolly, “Atrial fibrillation: hypertension as a causative agent, risk factor for complications, and potential therapeutic target,” American Journal of Cardiology, vol. 91, no. 10, pp. 9G–14G, 2003. View at Publisher · View at Google Scholar · View at Scopus
  68. A. H. Gradman and F. Alfayoumi, “From left ventricular hypertrophy to congestive heart failure: management of hypertensive heart disease,” Progress in Cardiovascular Diseases, vol. 48, no. 5, pp. 326–341, 2006. View at Publisher · View at Google Scholar · View at Scopus
  69. N. Frey and E. N. Olson, “Modulating cardiac hypertrophy by manipulating myocardial lipid metabolism?” Circulation, vol. 105, no. 10, pp. 1152–1154, 2002. View at Google Scholar · View at Scopus
  70. G. S. Francis and J. B. Young, “The looming polypharmacy crisis in the management of patients with heart failure. Potential solutions,” Cardiology Clinics, vol. 19, no. 4, pp. 541–545, 2001. View at Google Scholar · View at Scopus
  71. M. E. Otto, M. Belohlavek, B. Khandheria, G. Gilman, A. Svatikova, and V. Somers, “Comparison of right and left ventricular function in obese and nonobese men,” American Journal of Cardiology, vol. 93, no. 12, pp. 1569–1572, 2004. View at Publisher · View at Google Scholar · View at Scopus
  72. M. Asakawa, H. Takano, T. Nagai et al., “Peroxisome proliferator-activated receptor γ plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo,” Circulation, vol. 105, no. 10, pp. 1240–1246, 2002. View at Publisher · View at Google Scholar · View at Scopus
  73. H. Takano, Y. Zou, H. Akazawa et al., “Inhibitory molecules in signal transduction pathways of cardiac hypertrophy,” Hypertension Research, vol. 25, no. 4, pp. 491–498, 2002. View at Google Scholar · View at Scopus
  74. K. Yamamoto, R. Ohki, R. T. Lee, U. Ikeda, and K. Shimada, “Peroxisome proliferator-activated receptor γ activators inhibit cardiac hypertrophy in cardiac myocytes,” Circulation, vol. 104, no. 14, pp. 1670–1675, 2001. View at Google Scholar · View at Scopus
  75. S. Z. Duan, C. Y. Ivashchenko, M. W. Russell, D. S. Milstone, and R. M. Mortensen, “Cardiomyocyte-specffic knockout and agonist of peroxisome proliferator-activated receptor-γ both induce cardiac hypertrophy in mice,” Circulation Research, vol. 97, no. 4, pp. 372–379, 2005. View at Publisher · View at Google Scholar · View at Scopus
  76. G. Ding, M. Fu, Q. Qin et al., “Cardiac peroxisome proliferator-activated receptor γ is essential in protecting cardiomyocytes from oxidative damage,” Cardiovascular Research, vol. 76, no. 2, pp. 269–279, 2007. View at Publisher · View at Google Scholar · View at Scopus
  77. N.-H. Son, T.-S. Park, H. Yamashita et al., “Cardiomyocyte expression of PPARγ leads to cardiac dysfunction in mice,” Journal of Clinical Investigation, vol. 117, no. 10, pp. 2791–2801, 2007. View at Publisher · View at Google Scholar · View at Scopus
  78. H. Hasegawa, H. Takano, Y. Zou et al., “Pioglitazone, a peroxisome proliferator-activated receptor γ activator, ameliorates experimental autoimmune myocarditis by modulating Th1/Th2 balance,” Journal of Molecular and Cellular Cardiology, vol. 38, no. 2, pp. 257–265, 2005. View at Publisher · View at Google Scholar · View at Scopus
  79. T. Toyozaki, T. Saito, H. Shiraishi et al., “Macrophage inflammatory protein-1α relates to the recruitment of inflammatory cells in myosin-induced autoimmune myocarditis in rats,” Laboratory Investigation, vol. 81, no. 7, pp. 929–936, 2001. View at Google Scholar · View at Scopus
  80. Z. Yuan, Y. Liu, Y. Liu et al., “Peroxisome proliferation-activated receptor-γ ligands ameliorate experimental autoimmune myocarditis,” Cardiovascular Research, vol. 59, no. 3, pp. 685–694, 2003. View at Publisher · View at Google Scholar · View at Scopus
  81. B. Vergès, “Clinical interest of PPARs ligands,” Diabetes and Metabolism, vol. 30, no. 1, pp. 7–12, 2004. View at Google Scholar · View at Scopus
  82. P. C. Stafylas, P. A. Sarafidis, and A. N. Lasaridis, “The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality,” International Journal of Cardiology, vol. 131, no. 3, pp. 298–304, 2009. View at Publisher · View at Google Scholar · View at Scopus
  83. T. Mazzone, P. M. Meyer, S. B. Feinstein et al., “Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial,” Journal of the American Medical Association, vol. 296, no. 21, pp. 2572–2581, 2006. View at Publisher · View at Google Scholar · View at Scopus
  84. S. E. Nissen, S. J. Nicholls, K. Wolski et al., “Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial,” Journal of the American Medical Association, vol. 299, no. 13, pp. 1561–1573, 2008. View at Publisher · View at Google Scholar · View at Scopus
  85. J. A. Dormandy, B. Charbonnel, D. J. Eckland et al., “Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial,” Lancet, vol. 366, no. 9493, pp. 1279–1289, 2005. View at Publisher · View at Google Scholar · View at Scopus
  86. E. Erdmann, J. A. Dormandy, B. Charbonnel, M. Massi-Benedetti, I. K. Moules, and A. M. Skene, “The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction. Results from the PROactive (PROactive 05) study,” Journal of the American College of Cardiology, vol. 49, no. 17, pp. 1772–1780, 2007. View at Publisher · View at Google Scholar · View at Scopus
  87. R. Wilcox, M.-G. Bousser, D. J. Betteridge et al., “Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04),” Stroke, vol. 38, no. 3, pp. 865–873, 2007. View at Publisher · View at Google Scholar · View at Scopus
  88. E. Mannucci, M. Monami, C. Lamanna, G. F. Gensini, and N. Marchionni, “Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials,” Diabetes, Obesity and Metabolism, vol. 10, no. 12, pp. 1221–1238, 2008. View at Publisher · View at Google Scholar · View at Scopus
  89. R. Wilcox, S. Kupfer, and E. Erdmann, “Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone clinical trial in macro vascular events (PROactive 10),” American Heart Journal, vol. 155, no. 4, pp. 712–717, 2008. View at Publisher · View at Google Scholar · View at Scopus
  90. S. E. Nissen and K. Wolski, “Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes,” New England Journal of Medicine, vol. 356, no. 24, pp. 2457–2471, 2007. View at Google Scholar · View at Scopus
  91. G. A. Diamond, L. Bax, and S. Kaul, “Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death,” Annals of Internal Medicine, vol. 147, no. 8, pp. 578–581, 2007. View at Google Scholar · View at Scopus
  92. A. V. Hernandez, E. Walker, J. P. A. Ioannidis, and M. W. Kattan, “Challenges in meta-analysis of randomized clinical trials for rare harmful cardiovascular events: the case of rosiglitazone,” American Heart Journal, vol. 156, no. 1, pp. 23–30, 2008. View at Publisher · View at Google Scholar · View at Scopus
  93. G. Rücker and M. Schumacher, “Simpson's paradox visualized: the example of the rosiglitazone meta-analysis,” BMC Medical Research Methodology, vol. 8, article no. 34, 2008. View at Publisher · View at Google Scholar · View at Scopus
  94. S. Singh, Y. K. Loke, and C. D. Furberg, “Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis,” Journal of the American Medical Association, vol. 298, no. 10, pp. 1189–1195, 2007. View at Publisher · View at Google Scholar · View at Scopus
  95. I. J. Dahabreh and K. Economopoulos, “Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone,” Clinical Trials, vol. 5, no. 2, pp. 116–120, 2008. View at Publisher · View at Google Scholar · View at Scopus
  96. M. Monami, N. Marchionni, and E. Mannucci, “Winners and losers at the rosiglitazone gamble. A meta-analytical approach at the definition of the cardiovascular risk profile of rosiglitazone,” Diabetes Research and Clinical Practice, vol. 82, no. 1, pp. 48–57, 2008. View at Publisher · View at Google Scholar · View at Scopus
  97. R. B. Goldberg, D. M. Kendall, M. A. Deeg et al., “A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia,” Diabetes Care, vol. 28, no. 7, pp. 1547–1554, 2005. View at Publisher · View at Google Scholar · View at Scopus
  98. G. Orasanu, O. Ziouzenkova, P. R. Devchand et al., “The peroxisome proliferator-activated receptor-γ agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-α-dependent manner in vitro and in vivo in mice,” Journal of the American College of Cardiology, vol. 52, no. 10, pp. 869–881, 2008. View at Publisher · View at Google Scholar · View at Scopus
  99. C. Werner, C. H. Kamani, C. Gensch, M. Böhm, and U. Laufs, “The peroxisome proliferator-activated receptor-γ agonist pioglitazone increases number and function of endothelial progenitor cells in patients with coronary artery disease and normal glucose tolerance,” Diabetes, vol. 56, no. 10, pp. 2609–2615, 2007. View at Publisher · View at Google Scholar · View at Scopus
  100. H. J. Dargie, P. R. Hildebrandt, G. A. J. Riegger et al., “A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York heart association functional class I or II heart failure,” Journal of the American College of Cardiology, vol. 49, no. 16, pp. 1696–1704, 2007. View at Publisher · View at Google Scholar · View at Scopus
  101. R. M. Lago, P. P. Singh, and R. W. Nesto, “Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials,” Lancet, vol. 370, no. 9593, pp. 1129–1136, 2007. View at Publisher · View at Google Scholar · View at Scopus
  102. H. D. Berlie, J. S. Kalus, and L. A. Jaber, “Thiazolidinediones and the risk of edema: a meta-analysis,” Diabetes Research and Clinical Practice, vol. 76, no. 2, pp. 279–289, 2007. View at Publisher · View at Google Scholar · View at Scopus
  103. C.-H. Wang, R. D. Weisel, P. P. Liu, P. W. M. Fedak, and S. Verma, “Glitazones and heart failure: critical appraisal for the clinician,” Circulation, vol. 107, no. 10, pp. 1350–1354, 2003. View at Publisher · View at Google Scholar · View at Scopus
  104. K. B. Sotiropoulos, A. Clermont, Y. Yasuda et al., “Adipose-specific effect of rosiglitazone on vascular permeability and protein kinase C activation: novel mechanism for PPARgamma agonist's effects on edema and weight gain,” The FASEB Journal, vol. 20, no. 8, pp. 1203–1205, 2006. View at Publisher · View at Google Scholar · View at Scopus
  105. H. Zhang, A. Zhang, D. E. Kohan, R. D. Nelson, F. J. Gonzalez, and T. Yang, “Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention,” roceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 26, pp. 9406–9411, 2005. View at Google Scholar
  106. Y. Guan, C. Hao, D. R. Cha et al., “Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption,” Nature Medicine, vol. 11, no. 8, pp. 861–866, 2005. View at Google Scholar
  107. M. St John Sutton, M. Rendell, P. Dandona et al., “A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes,” Diabetes Care, vol. 25, no. 11, pp. 2058–2064, 2002. View at Google Scholar · View at Scopus
  108. R. W. Nesto, D. Bell, R. O. Bonow et al., “Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association,” Circulation, vol. 108, no. 23, pp. 2941–2948, 2003. View at Publisher · View at Google Scholar · View at Scopus
  109. R. E. Schmieder, “Mechanisms for the clinical benefits of angiotensin II receptor blockers,” American Journal of Hypertension, vol. 18, no. 5, pp. 720–730, 2005. View at Publisher · View at Google Scholar · View at Scopus
  110. S. C. Benson, H. A. Pershadsingh, C. I. Ho et al., “Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity,” Hypertension, vol. 43, no. 5, pp. 993–1002, 2004. View at Publisher · View at Google Scholar · View at Scopus
  111. A. B. Benson III, J. A. Ajani, R. B. Catalano et al., “Recommended guidelines for the treatment of cancer treatment-induced diarrhea,” Journal of Clinical Oncology, vol. 22, no. 14, pp. 2918–2926, 2004. View at Publisher · View at Google Scholar · View at Scopus
  112. R. Clasen, M. Schupp, A. Foryst-Ludwig et al., “PPARγ-activating angiotensin type-1 receptor blockers induce adiponectin,” Hypertension, vol. 46, no. 1, pp. 137–143, 2005. View at Publisher · View at Google Scholar · View at Scopus
  113. N. Ouchi, H. Kobayashi, S. Kihara et al., “Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells,” The Journal of Biological Chemistry, vol. 279, no. 2, pp. 1304–1309, 2004. View at Google Scholar
  114. A. Honda, K. Matsuura, N. Fukushima, Y. Tsurumi, H. Kasanuki, and N. Hagiwara, “Telmisartan induces proliferation of human endothelial progenitor cells via PPARγ-dependent PI3K/Akt pathway,” Atherosclerosis, vol. 205, no. 2, pp. 376–384, 2009. View at Publisher · View at Google Scholar · View at Scopus
  115. S. Yusuf, K. K. Teo, J. Pogue et al., “Telmisartan, ramipril, or both in patients at high risk for vascular events,” New England Journal of Medicine, vol. 358, no. 15, pp. 1547–1559, 2008. View at Publisher · View at Google Scholar · View at Scopus